Fig. 2: Integrated analyses of metabolomics and transcriptomics data showing the critical metabolic dysregulations of patients with ESCC. | Cell Death Discovery

Fig. 2: Integrated analyses of metabolomics and transcriptomics data showing the critical metabolic dysregulations of patients with ESCC.

From: Purine salvage–associated metabolites as biomarkers for early diagnosis of esophageal squamous cell carcinoma: a diagnostic model–based study

Fig. 2

A Diagram showing the procedure for the integrated analysis of tissue metabolome and transcriptome in the discovery cohort. Untargeted metabolic detection and transcriptome sequencing were carried out for paired tissues from 23 patients with ESCC. B Volcano plot showing the DEGs in the tumor tissue. C Enriched KEGG pathways identified in the hypergeometric distribution test for DEGs and metabolites. D Dysregulated purine salvage pathway in patients with ESCC. Synchronous upregulated expression of the gene (HPRT1) and its metabolic substrates (hypoxanthine and xanthine) in patients with ESCC, leading to enhanced synthesis of guanosine monophosphate. E ROC curves showing the diagnostic performance of the combination of two potential biomarkers (hypoxanthine and xanthine) in the discovery cohort. Red: tumor tissues vs NAT; blue: serum of healthy subjects vs serum of patients with ESCC. F ROC curves showing the diagnostic performances of the combination of two potential biomarkers (hypoxanthine and xanthine) in the external validation cohort. Red: serum of healthy subjects vs serum of patients with ESCC; yellow: serum of healthy subjects vs patients with colorectal cancer; green: serum of healthy subjects vs patients with lung cancer. DEGs differentially expressed genes, ESCC esophageal squamous cell carcinoma, KEGG Kyoto Encyclopedia of Genes and Genomes, ROC receiver operating characteristic, NAT normal tissues adjacent to the tumor.

Back to article page